Pooya Torkian

Dr. Pooya Torkian


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2018 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
HEHamed Esfandiari
Hamed Esfandiari
PSPriyal Shah
Priyal Shah
PTPooya Torkian
Pooya Torkian
ICIan P. Conner
Ian P. Conner
JSJoel S Schuman
Joel S Schuman
NLNils Loewen
Nils Loewen

19 June 2018 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
SAShahram Akhlaghpour
Shahram Akhlaghpour
PTPooya Torkian
Pooya Torkian
JGJafar Golzarian
Jafar Golzarian

6 June 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
RTReza Talaie
Reza Talaie
PTPooya Torkian
Pooya Torkian
ACAlexander Clayton
Alexander Clayton
SWStephanie Wallace
Stephanie Wallace
HCHoiwan Cheung
Hoiwan Cheung
JGJafar Golzarian
Jafar Golzarian
Osteoarthritis (OA) is the major cause of disability, affecting over 30 million US adults. Continued research into the role of neovascularization and inflammation related to osteoarthritis in large-animal models and human clinical trials is paramount. Recent literature on the pathogenetic model of OA has refocused on low-level inflammation, resulting in joint remodeling. As a result, this has redirected osteoarthritis research toward limiting or treating joint changes associated with persistent synovitis. The overall goal of this review is to better understand the cellular and tissue-specific mechanisms of inflammation in relation to a novel OA treatment modality, Genicular Artery Embolization (GAE). This article also assesses the utility and mechanism of periarticular neovascular embolization for the treatment of OA with a particular emphasis on the balance between pro-angiogenic and anti-angiogenic cytokines, inflammatory biomarkers, and imaging changes.

30 July 2019 in Journal of Glaucoma
Verified
Journal Article
Closed access
HEHamed Esfandiari
Hamed Esfandiari
SKSudhi P. Kurup
Sudhi P. Kurup
PTPooya Torkian
Pooya Torkian
MMMarilyn B. Mets
Marilyn B. Mets
BRBahram Rahmani
Bahram Rahmani
ATAngelo P. Tanna
Angelo P. Tanna
Precis: In this retrospective case series, both Baerveldt and Ahmed glaucoma drainage devices resulted in good long-term outcomes in eyes with pediatric glaucoma following cataract surgery (GFCS). Background: The aim of this study was to describe the long-term safety and efficacy of primary glaucoma drainage device surgery in patients with pediatric GFCS. Methods: We retrospectively identified 28 eyes of 28 patients with GFCS that underwent tube shunt surgery with the Ahmed Glaucoma Valve or Baerveldt Glaucoma Implant. The primary outcome measure was a surgical failure, defined as intraocular pressure (IOP) >21 mm Hg or not reduced by 20% below baseline on 2 consecutive follow-up visits after 3 months, IOP <5 mm Hg on 2 consecutive follow-up visits after 3 months, and reoperation for glaucoma. Results: The mean duration between cataract removal and the diagnosis of glaucoma was 3.6±1.5 years. Kaplan-Meier survival curves indicated a mean time to failure of 41.9±2.1 months after drainage device surgery. The cumulative probability of failure at 1, 2, 3, and 4 years was 3.6%, 19%, 28%, and 28%. IOP was significantly decreased from 29.3±4.1 mm Hg preoperatively to 17.6±1.6 mm Hg at the final follow-up visit (P<0.001). The number of glaucoma medications at baseline was 3.1±0.6, which decreased to 2.1±0.7 at the final visit (P=0.001). Conclusions: Glaucoma drainage device surgery results in good long-term outcomes in patients with GFCS.

9 September 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
PTPooya Torkian
Pooya Torkian
JAJavid Azadbakht
Javid Azadbakht
Pietro Andrea BonaffiniPietro Andrea Bonaffini
Pietro Andrea Bonaffini
BABehrang Amini
Behrang Amini
MCMajid Chalian
Majid Chalian
Plasma cell dyscrasias are estimated to newly affect almost 40,000 people in 2022. They fall on a spectrum of diseases ranging from relatively benign to malignant, the malignant end of the spectrum being multiple myeloma (MM). The International Myeloma Working Group (IMWG) has traditionally outlined the diagnostic criteria and therapeutic management of MM. In the last two decades, novel imaging techniques have been employed for MM to provide more information that can guide not only diagnosis and staging, but also treatment efficacy. These imaging techniques, due to their low invasiveness and high reliability, have gained significant clinical attention and have already changed the clinical practice. The development of functional MRI sequences such as diffusion weighted imaging (DWI) or intravoxel incoherent motion (IVIM) has made the functional assessment of lesions feasible. Moreover, the growing availability of positron emission tomography (PET)–magnetic resonance imaging (MRI) scanners is leading to the potential combination of sensitive anatomical and functional information in a single step. This paper provides an organized framework for evaluating the benefits and challenges of novel and more functional imaging techniques used for the management of patients with plasma cell dyscrasias, notably MM.

6 May 2022 in Annals of Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
RTReza Talaie
Reza Talaie
PTPooya Torkian
Pooya Torkian
OAOmid Amili
Omid Amili
YAYasmina Aboufirass
Yasmina Aboufirass
NRNassir Rostambeigi
Nassir Rostambeigi
JGJafar Golzarian
Jafar Golzarian